A Phase 2 interventional study of Dupilumab and Placebo matching dupilumab in Peanut Allergy, sponsored by Regeneron Pharmaceuticals. Completed at 25 sites in United States. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2024-02-07.
Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 99 studies in Peanut Hypersensitivity with a site in United States — 10 open to participants now, 16 under way, 3 of them phase 3. Peanut Hypersensitivity · United States.
Among the 99 studies in Peanut Hypersensitivity with a site in United States, this one is the 21st largest by enrollment of the 87 interventional ones that give a count, is one of 4 that started in 2018, is one of 26 in phase 2, and was the 60th registered.
166 studies on the registry are indexed under Peanut Hypersensitivity; 27 are open to participants now.
Browse Peanut Hypersensitivity studies →10 of the 99 studies in Peanut Hypersensitivity with a site in United States are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States
Ages 12–65
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 12 mo–17 yrs
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 12–55
N-Fold, LLC · Sites in United States
Ages 14–50 · Healthy volunteers
Mabylon AG · Sites in United States
Ages 12–55 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 18 Peanut Hypersensitivity studies recruiting now, 2 (11%) set no upper age limit and 16 (89%) stop at 75 or younger; 15 take children under 18; 6 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
99 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 36 · Phase 2 43 · Phase 3 17
First in 1996; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 148 is above the median of 50 across 127 interventional studies indexed under Peanut Hypersensitivity.
Median enrollment 47 across the 87 interventional studies, 270 across the 11 observational. Of the 77 that completed or were terminated, 50 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 99 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Regeneron Pharmaceuticals has 2 studies filed under Peanut Hypersensitivity — fewer than ten, so there is no comparison to draw.
6 of the studies in Peanut Hypersensitivity with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07003919Phase 3DBV TechnologiesSafety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers) | 2026-11 |
| NCT05476497Allergy TherapeuticsPhase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects | 2026-11 |
| NCT04222491Massachusetts General HospitalFood Oral Immunotherapy for Peanut Allergy | 2026-12 |
| NCT05695261Rima RachidEvaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients | 2027-01-11 |
| NCT07220811RAPT Therapeutics, Inc., a member of the GSK plc group of companiesPhase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy | 2027-03-16 |
Add all 6 to your calendar (.ics) → With an account.
Among the 99 studies in Peanut Hypersensitivity with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Primary objective is to assess whether dupilumab as adjunct to AR101 compared to placebo improves desensitization at the completion of up-dosing, defined as an increase in the proportion of participants who pass a post up-dosing double-blind placebo-controlled food challenge (DBPCFC) at visit 16.
Secondary objectives are:
Key Inclusion Criteria:
Key Exclusion Criteria:
Asthma at time of enrollment with any of the following:
Note: Other protocol Inclusion/Exclusion Criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participant randomization of a ratio of 2 active dupilumab arms
Drug: Dupilumab · Drug: AR101
Participant randomization of a ratio of 1 placebo arm
Drug: Placebo matching dupilumab · Drug: AR101
Dupilumab will be administered subcutaneously (SC) in a single-use, pre-filled glass syringe every two weeks (Q2W)
Placebo matching dupilumab is prepared in the same formulation without the addition of protein
Drug pages: Panobacumab · Iclaprim, (r)-
AR101 will be provided in dose-escalating capsules and then sachets during maintenance phase
Percentage of Participants Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 Who Passed a Post Up-dosing Double-blind, Placebo-controlled Food Challenge (DBPCFC) With 2044 mg (Cumulative) Peanut Protein at Visit 16 (Week 28 to 40)
Symptoms considered to be allergic were graded using the Consortium of Food Allergy Research (CoFAR) Grading Scale for Systemic Allergic Reactions. The allergic reaction is measured on a 1-5 scale, with grade 1 being mild, grade 2 being moderate, grade 3 being severe, grade 4 being life threatening, and grade 5 as death. the higher the grade, the more severe the allergic reaction. Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction. Percentage of participants treated with dupilumab plus AR101 vs placebo plus AR101 who passed a post up-dosing DBPCFC with 2044 mg (Cumulative) peanut protein at Visit 16 (Week 28 to 40) was reported. Cumulative data during the specified period was calculated as the average of all available post-randomization values during the specified time period (Week 28 to Week 40).
Time frame: At Visit 16 (Week 28 to 40)
Change From Baseline in Cumulative Tolerated Dose (Log Transformed) of Peanut Protein During a DBPCFC at Visit 16 (Week 28 to 40) in Participants Treated With Dupilumab Plus AR101 vs Placebo Plus AR101
Change from baseline in cumulative tolerated dose (log transformed) of peanut protein during a DBPCFC at Visit 16 (Week 28 to 40) in participants treated with dupilumab plus AR101 vs placebo plus AR101 was reported. Cumulative tolerated dose during the specified period was calculated as the mean of all available post-randomization values during the specified time period (Week 28 to Week 40).
Time frame: Baseline, Visit 16 (Week 28 to 40)
Percentage of Participants Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 Who Reached the 300 mg/Day Dose of AR101 by Visit 16 (Week 28 to 40)
Percentage of participants treated with dupilumab plus AR101 vs placebo plus AR101 who reached the 300 mg/day dose of AR101 by Visit 16 (Week 28 to 40) was reported. Cumulative data during the specified period was calculated as the average of all available post-randomization values during the specified time period (Week 28 to Week 40).
Time frame: At Visit 16 (Week 28 to 40)
Time From Randomization to the First Time When Participants Reached the 300 mg/Day Dose of AR101 During the Up-dosing Treatment Phase by Visit 16 (Week 28 to 40)
Time (in days) from randomization to the first time when participants reached the 300 mg/day dose of AR101 during the up-dosing treatment phase by Visit 16 (Week 28 to 40) was reported. If participants did not reach the 300 mg/day dose of AR101 during the 28-week treatment period, they were censored at the date of their last visit during pre-AR101 dosing and AR101 up-dosing treatment period. Analysis was performed using Kaplan-Meier Estimated method.
Time frame: At Visit 16 (Week 28 to 40)
Percentage of Participants (Continuously) Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 Who Passed a Post Maintenance DBPCFC With 2044 mg (Cumulative) Peanut Protein at Visit 22 (Week 52 to 64)
Symptoms considered to be allergic were graded using the CoFAR Grading Scale for Systemic Allergic Reactions. The allergic reaction is measured on a 1-5 scale, with grade 1 being mild, grade 2 being moderate, grade 3 being severe, grade 4 being life threatening, and grade 5 as death. the higher the grade, the more severe the allergic reaction. Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction. Percentage of participants (continuously) treated with dupilumab plus AR101 vs placebo plus AR101 who passed a post maintenance DBPCFC with 2044 mg (cumulative) peanut protein at Visit 22 (Week 52 to 64) was reported. Cumulative data during the specified period was calculated as the average of all available post-randomization values during the specified time period (Week 52 to Week 64).
Time frame: At Visit 22 (Week 52 to 64)
Change From Baseline in Cumulative Tolerated Dose (Log Transformed) of Peanut Protein During a DBPCFC at Visit 22 (Week 52 to 64) in Participants (Continuously) Treated With Dupilumab Plus AR101 vs Placebo Plus AR101
Change from baseline in cumulative tolerated dose (log transformed) of peanut protein during a DBPCFC at Visit 22 (Week 52 to 64) in participants (continuously) treated with dupilumab plus AR101 vs placebo plus AR101 was reported. Cumulative tolerated dose during the specified period was calculated as the mean of all available post-randomization values during the specified time period (Week 52 to Week 64).
Time frame: Baseline, Visit 22 (Week 52 to 64)
Percentage of Participants (Previously) Treated With Dupilumab + AR101/Placebo +AR101 vs Placebo Plus AR101 Who Passed a Post Maintenance DBPCFC With 2044 mg (Cumulative) Peanut Protein at Visit 22 (Week 52 to 64)
Symptoms considered to be allergic were graded using the CoFAR Grading Scale for Systemic Allergic Reactions. The allergic reaction is measured on a 1-5 scale, with grade 1 being mild, grade 2 being moderate, grade 3 being severe, grade 4 being life threatening, and grade 5 as death. the higher the grade, the more severe the allergic reaction. Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction. Percentage of participants (previously) treated with dupilumab plus AR101 (and re-randomized to placebo plus AR101) vs placebo plus AR101 who "pass" a post maintenance DBPCFC with 2044 mg (cumulative) peanut protein at Visit 22 (Week 52 to 64) was reported. Cumulative data during the specified period was calculated as the average of all available post-randomization values during the specified time period (Week 52 to Week 64).
Time frame: At Visit 22 (Week 52 to 64)
Change From Baseline in Cumulative Tolerated Dose (Log Transformed) of Peanut Protein During a DBPCFC at Visit 22 (Week 52 to 64) in Participants (Previously) Treated With Dupilumab + AR101/Placebo +AR101 vs Placebo Plus AR101
Change from baseline in cumulative tolerated dose (log transformed) of peanut protein during a DBPCFC at Visit 22 (Week 52 to 64) in participants (previously) treated with dupilumab plus AR101 (and re-randomized to placebo plus AR101) vs placebo plus AR101 was reported. Cumulative tolerated dose during the specified period was calculated as the mean of all available post-randomization values during the specified time period (Week 52 to Week 64).
Time frame: Baseline, Visit 22 (Week 52 to 64)
Percent Change From Baseline in Peanut-specific IgE in Participants Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 to Visit 16 (Week 28 to 40)
Percent change from baseline in peanut-specific IgE in participants treated with dupilumab + AR101 vs placebo + AR101 to Visit 16 (Week 28 to 40) was reported. Analysis was performed using Last observation carried forward (LOCF) method. Data reported during the specified period was calculated as the average of all available post-randomization values during the specified time period (Week 28 to Week 40).
Time frame: Baseline up to Visit 16 (Weeks 28 to 40)
Percent Change From Baseline in Peanut-specific IgE in Participants (Continuously) Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 to Visit 22 (Week 52 to 64)
Percent change from baseline in peanut-specific IgE in participants treated with dupilumab + AR101 vs placebo + AR101 to Visit 22 (Week 52 to 64) was reported. Analysis was performed using LOCF method. Data reported during the specified period was calculated as the average of all available post-randomization values during the specified time period (Week 52 to Week 64).
Time frame: Baseline up to Visit 22 (Week 52 to 64)
Percent Change From Baseline in Peanut-specific IgE in Participants (Continuously) Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 to Visit 25 (Weeks 64 to 76)
Percent change from baseline in peanut-specific IgE in participants treated with dupilumab + AR101 vs placebo + AR101 to Visit 25 (Week 64 to 76) was reported. Analysis was performed using LOCF method. Data reported during the specified period was calculated as the average of all available post-randomization values during the specified time period (Week 64 to Week 76).
Time frame: Baseline up to Visit 25 (Weeks 64 to 76)
| Milestone | Pre-AR101 Dosing Period: Placebo-matched Dupilumab | Pre-AR101 Dosing Period: Dupilumab | AR101 Up-dosing Period: Placebo + AR101 | AR101 Up-dosing Period: Dupilumab + AR101 | AR101 Maintenance Period: Placebo-matched Dupilumab + AR101 Continued | AR101 Maintenance Period: Dupilumab + AR101 Continued | AR101 Maintenance Period: Dupilumab + AR101/Placebo-matched Dupilumab + AR101 |
|---|---|---|---|---|---|---|---|
| Started | 50 | 98 | 0 | 0 | 0 | 0 | 0 |
| Completed | 49 | 96 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 1 | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Sponsor decision | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Pre-AR101 Dosing Period: Placebo-matched Dupilumab | Pre-AR101 Dosing Period: Dupilumab | AR101 Up-dosing Period: Placebo + AR101 | AR101 Up-dosing Period: Dupilumab + AR101 | AR101 Maintenance Period: Placebo-matched Dupilumab + AR101 Continued | AR101 Maintenance Period: Dupilumab + AR101 Continued | AR101 Maintenance Period: Dupilumab + AR101/Placebo-matched Dupilumab + AR101 |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 49 | 96 | 0 | 0 | 0 |
| Completed | 0 | 0 | 39 | 88 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 10 | 8 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 7 | 3 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Investigator/sponsor decision | 0 | 0 | 1 | 2 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Chronic/recurrent gi aes/symptoms | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Milestone | Pre-AR101 Dosing Period: Placebo-matched Dupilumab | Pre-AR101 Dosing Period: Dupilumab | AR101 Up-dosing Period: Placebo + AR101 | AR101 Up-dosing Period: Dupilumab + AR101 | AR101 Maintenance Period: Placebo-matched Dupilumab + AR101 Continued | AR101 Maintenance Period: Dupilumab + AR101 Continued | AR101 Maintenance Period: Dupilumab + AR101/Placebo-matched Dupilumab + AR101 |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 40 | 44 | 44 |
| Randomized and treated | 0 | 0 | 0 | 0 | 40 | 43 | 42 |
| Completed | 0 | 0 | 0 | 0 | 36 | 41 | 41 |
| Not completed | 0 | 0 | 0 | 0 | 4 | 3 | 3 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 3 | 1 | 1 |
| Withdrew: Investigator/sponsor decision | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Randomized, but not treated | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
Symptoms considered to be allergic were graded using the Consortium of Food Allergy Research (CoFAR) Grading Scale for Systemic Allergic Reactions. The allergic reaction is measured on a 1-5 scale, with grade 1 being mild, grade 2 being moderate, grade 3 being severe, grade 4 being life threatening, and grade 5 as death. the higher the grade, the more severe the allergic reaction. Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction. Percentage of participants treated with dupilumab plus AR101 vs placebo plus AR101 who passed a post up-dosing DBPCFC with 2044 mg (Cumulative) peanut protein at Visit 16 (Week 28 to 40) was reported. Cumulative data during the specified period was calculated as the average of all available post-randomization values during the specified time period (Week 28 to Week 40).
| Percentage of participants | AR101 Up-dosing Period: Placebo + AR101 | AR101 Up-dosing Period: Dupilumab + AR101 |
|---|---|---|
| Percentage of Participants Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 Who Passed a Post Up-dosing Double-blind, Placebo-controlled Food Challenge (DBPCFC) With 2044 mg (Cumulative) Peanut Protein at Visit 16 (Week 28 to 40) | 35.90 (21.204 to 52.820) | 55.95 (44.695 to 66.778) |
Change from baseline in cumulative tolerated dose (log transformed) of peanut protein during a DBPCFC at Visit 16 (Week 28 to 40) in participants treated with dupilumab plus AR101 vs placebo plus AR101 was reported. Cumulative tolerated dose during the specified period was calculated as the mean of all available post-randomization values during the specified time period (Week 28 to Week 40).
| Log Transformed Milligrams | AR101 Up-dosing Period: Placebo + AR101 | AR101 Up-dosing Period: Dupilumab + AR101 |
|---|---|---|
| Change From Baseline in Cumulative Tolerated Dose (Log Transformed) of Peanut Protein During a DBPCFC at Visit 16 (Week 28 to 40) in Participants Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 | 3.78 ± 0.270 | 4.45 ± 0.205 |
Percentage of participants treated with dupilumab plus AR101 vs placebo plus AR101 who reached the 300 mg/day dose of AR101 by Visit 16 (Week 28 to 40) was reported. Cumulative data during the specified period was calculated as the average of all available post-randomization values during the specified time period (Week 28 to Week 40).
| Percentage of participants | AR101 Up-dosing Period: Placebo + AR101 | AR101 Up-dosing Period: Dupilumab + AR101 |
|---|---|---|
| Percentage of Participants Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 Who Reached the 300 mg/Day Dose of AR101 by Visit 16 (Week 28 to 40) | 76.92 (60.674 to 88.866) | 89.29 (80.633 to 94.982) |
Time (in days) from randomization to the first time when participants reached the 300 mg/day dose of AR101 during the up-dosing treatment phase by Visit 16 (Week 28 to 40) was reported. If participants did not reach the 300 mg/day dose of AR101 during the 28-week treatment period, they were censored at the date of their last visit during pre-AR101 dosing and AR101 up-dosing treatment period. Analysis was performed using Kaplan-Meier Estimated method.
| Days | AR101 Up-dosing Period: Placebo + AR101 | AR101 Up-dosing Period: Dupilumab + AR101 |
|---|---|---|
| Time From Randomization to the First Time When Participants Reached the 300 mg/Day Dose of AR101 During the Up-dosing Treatment Phase by Visit 16 (Week 28 to 40) | 164.6 ± 38.43 | 167.5 ± 32.01 |
Symptoms considered to be allergic were graded using the CoFAR Grading Scale for Systemic Allergic Reactions. The allergic reaction is measured on a 1-5 scale, with grade 1 being mild, grade 2 being moderate, grade 3 being severe, grade 4 being life threatening, and grade 5 as death. the higher the grade, the more severe the allergic reaction. Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction. Percentage of participants (continuously) treated with dupilumab plus AR101 vs placebo plus AR101 who passed a post maintenance DBPCFC with 2044 mg (cumulative) peanut protein at Visit 22 (Week 52 to 64) was reported. Cumulative data during the specified period was calculated as the average of all available post-randomization values during the specified time period (Week 52 to Week 64).
| Percentage of participants | AR101 Maintenance Period: Placebo-matched Dupilumab + AR101 Continued | AR101 Maintenance Period: Dupilumab + AR101 Continued |
|---|---|---|
| Percentage of Participants (Continuously) Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 Who Passed a Post Maintenance DBPCFC With 2044 mg (Cumulative) Peanut Protein at Visit 22 (Week 52 to 64) | 47.50 (31.512 to 63.872) | 56.82 (41.034 to 71.651) |
Change from baseline in cumulative tolerated dose (log transformed) of peanut protein during a DBPCFC at Visit 22 (Week 52 to 64) in participants (continuously) treated with dupilumab plus AR101 vs placebo plus AR101 was reported. Cumulative tolerated dose during the specified period was calculated as the mean of all available post-randomization values during the specified time period (Week 52 to Week 64).
| Log Transformed Milligrams | AR101 Maintenance Period: Placebo-matched Dupilumab + AR101 Continued | AR101 Maintenance Period: Dupilumab + AR101 Continued |
|---|---|---|
| Change From Baseline in Cumulative Tolerated Dose (Log Transformed) of Peanut Protein During a DBPCFC at Visit 22 (Week 52 to 64) in Participants (Continuously) Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 | 4.19 ± 0.245 | 4.56 ± 0.250 |
Symptoms considered to be allergic were graded using the CoFAR Grading Scale for Systemic Allergic Reactions. The allergic reaction is measured on a 1-5 scale, with grade 1 being mild, grade 2 being moderate, grade 3 being severe, grade 4 being life threatening, and grade 5 as death. the higher the grade, the more severe the allergic reaction. Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction. Percentage of participants (previously) treated with dupilumab plus AR101 (and re-randomized to placebo plus AR101) vs placebo plus AR101 who "pass" a post maintenance DBPCFC with 2044 mg (cumulative) peanut protein at Visit 22 (Week 52 to 64) was reported. Cumulative data during the specified period was calculated as the average of all available post-randomization values during the specified time period (Week 52 to Week 64).
| Percentage of participants | AR101 Maintenance Period: Placebo-matched Dupilumab + AR101 Continued | AR101 Maintenance Period: Dupilumab + AR101/Placebo-matched Dupilumab + AR101 |
|---|---|---|
| Percentage of Participants (Previously) Treated With Dupilumab + AR101/Placebo +AR101 vs Placebo Plus AR101 Who Passed a Post Maintenance DBPCFC With 2044 mg (Cumulative) Peanut Protein at Visit 22 (Week 52 to 64) | 47.50 (31.512 to 63.872) | 45.45 (30.391 to 61.153) |
Change from baseline in cumulative tolerated dose (log transformed) of peanut protein during a DBPCFC at Visit 22 (Week 52 to 64) in participants (previously) treated with dupilumab plus AR101 (and re-randomized to placebo plus AR101) vs placebo plus AR101 was reported. Cumulative tolerated dose during the specified period was calculated as the mean of all available post-randomization values during the specified time period (Week 52 to Week 64).
| Log Transformed Milligrams | AR101 Maintenance Period: Placebo-matched Dupilumab + AR101 Continued | AR101 Maintenance Period: Dupilumab + AR101/Placebo-matched Dupilumab + AR101 |
|---|---|---|
| Change From Baseline in Cumulative Tolerated Dose (Log Transformed) of Peanut Protein During a DBPCFC at Visit 22 (Week 52 to 64) in Participants (Previously) Treated With Dupilumab + AR101/Placebo +AR101 vs Placebo Plus AR101 | 4.19 ± 0.245 | 4.14 ± 0.244 |
Percent change from baseline in peanut-specific IgE in participants treated with dupilumab + AR101 vs placebo + AR101 to Visit 16 (Week 28 to 40) was reported. Analysis was performed using Last observation carried forward (LOCF) method. Data reported during the specified period was calculated as the average of all available post-randomization values during the specified time period (Week 28 to Week 40).
| Percent change | AR101 Up-dosing Period: Placebo + AR101 | AR101 Up-dosing Period: Dupilumab + AR101 |
|---|---|---|
| Percent Change From Baseline in Peanut-specific IgE in Participants Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 to Visit 16 (Week 28 to 40) | 29.9 (3.3 to 82.2) | -60.6 (-68.1 to -50.5) |
Percent change from baseline in peanut-specific IgE in participants treated with dupilumab + AR101 vs placebo + AR101 to Visit 22 (Week 52 to 64) was reported. Analysis was performed using LOCF method. Data reported during the specified period was calculated as the average of all available post-randomization values during the specified time period (Week 52 to Week 64).
| Percent change | AR101 Maintenance Period: Placebo-matched Dupilumab + AR101 Continued | AR101 Maintenance Period: Dupilumab + AR101 Continued |
|---|---|---|
| Percent Change From Baseline in Peanut-specific IgE in Participants (Continuously) Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 to Visit 22 (Week 52 to 64) | 10.1 (-73.3 to 98.5) | -73.7 (-91.7 to -52.5) |
Percent change from baseline in peanut-specific IgE in participants treated with dupilumab + AR101 vs placebo + AR101 to Visit 25 (Week 64 to 76) was reported. Analysis was performed using LOCF method. Data reported during the specified period was calculated as the average of all available post-randomization values during the specified time period (Week 64 to Week 76).
| Percent change | AR101 Maintenance Period: Placebo-matched Dupilumab + AR101 Continued | AR101 Maintenance Period: Dupilumab + AR101 Continued |
|---|---|---|
| Percent Change From Baseline in Peanut-specific IgE in Participants (Continuously) Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 to Visit 25 (Weeks 64 to 76) | -7.2 (-84.6 to 94.7) | -73.9 (-91.6 to -45.5) |
Collected over From first dose of study drug up to Week 76. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pre-AR101 Dosing Period: Placebo-matched Dupilumab | 0/50 (0%) | 0/50 (0%) | 12/50 (24%) |
| Pre-AR101 Dosing Period: Dupilumab | 0/98 (0%) | 0/98 (0%) | 23/98 (23.5%) |
| AR101 Up-dosing Period: Placebo + AR101 | 0/49 (0%) | 0/49 (0%) | 34/49 (69.4%) |
| AR101 Up-dosing Period: Dupilumab + AR101 | 0/96 (0%) | 0/96 (0%) | 47/96 (49%) |
| AR101 Maintenance Period: Placebo-matched Dupilumab + AR101 Continued | 0/40 (0%) | 0/40 (0%) | 13/40 (32.5%) |
| AR101 Maintenance Period: Dupilumab + AR101 Continued | 0/42 (0%) | 1/42 (2.4%) | 17/42 (40.5%) |
| AR101 Maintenance Period: Dupilumab + AR101/Placebo-matched Dupilumab + AR101 | 0/43 (0%) | 0/43 (0%) | 15/43 (34.9%) |
| Event | Pre-AR101 Dosing Period: Placebo-matched Dupilumab | Pre-AR101 Dosing Period: Dupilumab | AR101 Up-dosing Period: Placebo + AR101 | AR101 Up-dosing Period: Dupilumab + AR101 | AR101 Maintenance Period: Placebo-matched Dupilumab + AR101 Continued | AR101 Maintenance Period: Dupilumab + AR101 Continued | AR101 Maintenance Period: Dupilumab + AR101/Placebo-matched Dupilumab + AR101 |
|---|---|---|---|---|---|---|---|
| AppendicitisInfections and infestations | 0/50 | 0/98 | 0/49 | 0/96 | 0/40 | 1/42 | 0/43 |
| Event | Pre-AR101 Dosing Period: Placebo-matched Dupilumab | Pre-AR101 Dosing Period: Dupilumab | AR101 Up-dosing Period: Placebo + AR101 | AR101 Up-dosing Period: Dupilumab + AR101 | AR101 Maintenance Period: Placebo-matched Dupilumab + AR101 Continued | AR101 Maintenance Period: Dupilumab + AR101 Continued | AR101 Maintenance Period: Dupilumab + AR101/Placebo-matched Dupilumab + AR101 |
|---|---|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 5/50 | 2/98 | 7/49 | 16/96 | 1/40 | 5/42 | 0/43 |
| VomitingGastrointestinal disorders | 0/50 | 2/98 | 8/49 | 5/96 | 1/40 | 2/42 | 0/43 |
| Abdominal painGastrointestinal disorders | 0/50 | 1/98 | 5/49 | 9/96 | 1/40 | 4/42 | 3/43 |
| DiarrhoeaGastrointestinal disorders | 0/50 | 1/98 | 5/49 | 5/96 | 0/40 | 3/42 | 1/43 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/50 | 1/98 | 5/49 | 4/96 | 0/40 | 1/42 | 0/43 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/50 | 0/98 | 4/49 | 2/96 | 4/40 | 0/42 | 1/43 |
| Abdominal pain upperGastrointestinal disorders | 0/50 | 1/98 | 2/49 | 8/96 | 1/40 | 1/42 | 2/43 |
| RashSkin and subcutaneous tissue disorders | 0/50 | 0/98 | 4/49 | 4/96 | 1/40 | 2/42 | 3/43 |
| HeadacheNervous system disorders | 1/50 | 2/98 | 4/49 | 5/96 | 1/40 | 1/42 | 2/43 |
| Rhinitis allergicRespiratory, thoracic and mediastinal disorders | 1/50 | 0/98 | 3/49 | 3/96 | 3/40 | 1/42 | 2/43 |
Full analysis set (FAS) included all randomized participants
| Age, Continuous(years) | Pre-AR101 Dosing Period: Placebo-matched Dupilumab | Pre-AR101 Dosing Period: Dupilumab | Total |
|---|---|---|---|
| Mean | 10.9 ± 3.00 | 11.3 ± 3.12 | 11.1 ± 3.08 |
| Sex: Female, Male(Participants) | Pre-AR101 Dosing Period: Placebo-matched Dupilumab | Pre-AR101 Dosing Period: Dupilumab | Total |
|---|---|---|---|
| Female | 18 | 38 | 56 |
| Male | 32 | 60 | 92 |
| Ethnicity (NIH/OMB)(Participants) | Pre-AR101 Dosing Period: Placebo-matched Dupilumab | Pre-AR101 Dosing Period: Dupilumab | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 8 | 12 |
| Not Hispanic or Latino | 45 | 87 | 132 |
| Unknown or Not Reported | 1 | 3 | 4 |
| Race/Ethnicity, Customized(participants) | Pre-AR101 Dosing Period: Placebo-matched Dupilumab | Pre-AR101 Dosing Period: Dupilumab | Total |
|---|---|---|---|
| White | 40 | 70 | 110 |
| Black or African American | 1 | 3 | 4 |
| Asian | 7 | 18 | 25 |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Other | 2 | 6 | 8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2018 to primary completion in Oct 2020, 24 months.
Results were first posted in Feb 2024, 3 years 3 months after primary completion. A results delay was requested in Oct 2021.
Of 18 phase 2 interventional studies under Peanut Hypersensitivity, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 58. This study's 24 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dupilumab